Silvia Aguilera
@silvia-aps.bsky.social
🇪🇺Today, as part of the @eular.org #PARE conference, we are visiting the European Parliament!
💪🏼 Proud to be representing ERN ReCONNET and @afosfolipido.bsky.social
💪🏼 Proud to be representing ERN ReCONNET and @afosfolipido.bsky.social
November 20, 2025 at 9:46 AM
🇪🇺Today, as part of the @eular.org #PARE conference, we are visiting the European Parliament!
💪🏼 Proud to be representing ERN ReCONNET and @afosfolipido.bsky.social
💪🏼 Proud to be representing ERN ReCONNET and @afosfolipido.bsky.social
In Ljubljana attending the ERN ReCONNET
#Transition training workshop! Looking forward to 2 days of exchanges and brainstorming together. Thank you to
Drs. Tadej Avcin and Mojca Zajc for the invitation 😊
#Transition training workshop! Looking forward to 2 days of exchanges and brainstorming together. Thank you to
Drs. Tadej Avcin and Mojca Zajc for the invitation 😊
November 13, 2025 at 9:04 AM
In Ljubljana attending the ERN ReCONNET
#Transition training workshop! Looking forward to 2 days of exchanges and brainstorming together. Thank you to
Drs. Tadej Avcin and Mojca Zajc for the invitation 😊
#Transition training workshop! Looking forward to 2 days of exchanges and brainstorming together. Thank you to
Drs. Tadej Avcin and Mojca Zajc for the invitation 😊
In Munich 🇩🇪 today with the @eular.org #PARE committee, working already on topics like the November Conference or 2026 EULAR Congress!
July 12, 2025 at 1:03 PM
In Munich 🇩🇪 today with the @eular.org #PARE committee, working already on topics like the November Conference or 2026 EULAR Congress!
Very happy to see again #PARE highlights in the closing session of #EULAR2025.
Michael Poelzl presented the #Highlights of the Patient and joint sessions presented by Peter Boyd, a 🧵
Michael Poelzl presented the #Highlights of the Patient and joint sessions presented by Peter Boyd, a 🧵
June 14, 2025 at 11:40 AM
Very happy to see again #PARE highlights in the closing session of #EULAR2025.
Michael Poelzl presented the #Highlights of the Patient and joint sessions presented by Peter Boyd, a 🧵
Michael Poelzl presented the #Highlights of the Patient and joint sessions presented by Peter Boyd, a 🧵
Reposted by Silvia Aguilera
Wonderful to hear from our @eular.org 2025 Edgar Stene Prize winner, Yvonne Balvers, who focused on the challenges of everyday activities that able bodied individuals may dismiss, and the persistence of trauma from childhood-onset RMDs into adulthood #eular2025
June 13, 2025 at 8:45 AM
Wonderful to hear from our @eular.org 2025 Edgar Stene Prize winner, Yvonne Balvers, who focused on the challenges of everyday activities that able bodied individuals may dismiss, and the persistence of trauma from childhood-onset RMDs into adulthood #eular2025
Reposted by Silvia Aguilera
Fantastic to see Sladjana, a STRATA-FIT patient research partner, presenting about the project and the evaluation of PRP involvement - partnership, communication, and support are critical #eular2025
June 13, 2025 at 8:49 AM
Fantastic to see Sladjana, a STRATA-FIT patient research partner, presenting about the project and the evaluation of PRP involvement - partnership, communication, and support are critical #eular2025
Reposted by Silvia Aguilera
Day 3 of #EULAR2025!
😴 We’ll discuss all things related to sleep & fatigue in this fascinating #PARE session
📍 C3
🕰️ 15:45-17:00
🗓️ Today!
👋🏼 See you there!
😴 We’ll discuss all things related to sleep & fatigue in this fascinating #PARE session
📍 C3
🕰️ 15:45-17:00
🗓️ Today!
👋🏼 See you there!
June 13, 2025 at 8:54 AM
Day 3 of #EULAR2025!
😴 We’ll discuss all things related to sleep & fatigue in this fascinating #PARE session
📍 C3
🕰️ 15:45-17:00
🗓️ Today!
👋🏼 See you there!
😴 We’ll discuss all things related to sleep & fatigue in this fascinating #PARE session
📍 C3
🕰️ 15:45-17:00
🗓️ Today!
👋🏼 See you there!
Reposted by Silvia Aguilera
The disconnect between patient and HCP priorities in Sjogren’s Disease endpoint priorities, specifically for pain, fatigue, and QoL is evident #eular2025
June 13, 2025 at 8:58 AM
The disconnect between patient and HCP priorities in Sjogren’s Disease endpoint priorities, specifically for pain, fatigue, and QoL is evident #eular2025
Reposted by Silvia Aguilera
Co-creation in practice: creating new clinical endpoints for primary Sjogren’s Disease between patient organisations, healthcare professionals, and industry professionals #eular2025
June 13, 2025 at 8:55 AM
Co-creation in practice: creating new clinical endpoints for primary Sjogren’s Disease between patient organisations, healthcare professionals, and industry professionals #eular2025
Reposted by Silvia Aguilera
Support requests for patient organisations regarding roll-out of electronic health records… again highlights the need for integrated collaborative approaches between healthcare providers/payers and patient organisations #eular2025
June 13, 2025 at 9:39 AM
Support requests for patient organisations regarding roll-out of electronic health records… again highlights the need for integrated collaborative approaches between healthcare providers/payers and patient organisations #eular2025
At the #EULAR2025 #PARE Poster tour, full room!
June 13, 2025 at 7:46 AM
At the #EULAR2025 #PARE Poster tour, full room!
Reposted by Silvia Aguilera
Daniel Aletaha, President of EULAR, always knows how to make an entrance! #EULAR2025 is officially underway! 👏 @eular.org
June 11, 2025 at 11:05 AM
Daniel Aletaha, President of EULAR, always knows how to make an entrance! #EULAR2025 is officially underway! 👏 @eular.org
Happy to be at #EULAR2025 in Barcelona!
June 11, 2025 at 11:29 AM
Happy to be at #EULAR2025 in Barcelona!
Reposted by Silvia Aguilera
IMPACT Trial
Certolizumab in high-risk pregnancies (APS + LAC):
• Complications: ↓ from 80% to 20%
• Gestational age: ↑ from 24 to 36.5 weeks
• Live births: ↑ from 38% to 93%
Huge congratulations to Jane Salmon & team – truly transformative results!
Certolizumab in high-risk pregnancies (APS + LAC):
• Complications: ↓ from 80% to 20%
• Gestational age: ↑ from 24 to 36.5 weeks
• Live births: ↑ from 38% to 93%
Huge congratulations to Jane Salmon & team – truly transformative results!
May 9, 2025 at 1:30 PM
IMPACT Trial
Certolizumab in high-risk pregnancies (APS + LAC):
• Complications: ↓ from 80% to 20%
• Gestational age: ↑ from 24 to 36.5 weeks
• Live births: ↑ from 38% to 93%
Huge congratulations to Jane Salmon & team – truly transformative results!
Certolizumab in high-risk pregnancies (APS + LAC):
• Complications: ↓ from 80% to 20%
• Gestational age: ↑ from 24 to 36.5 weeks
• Live births: ↑ from 38% to 93%
Huge congratulations to Jane Salmon & team – truly transformative results!
🤔Missed any #RheumaPreg25 sessions?
No worries! Join the highlights webinar on May 26. Contact @karenschreiber.bsky.social or @lauraandreoli.bsky.social to join the #ReHFaP mailing list 📩
No worries! Join the highlights webinar on May 26. Contact @karenschreiber.bsky.social or @lauraandreoli.bsky.social to join the #ReHFaP mailing list 📩
May 10, 2025 at 10:59 AM
🤔Missed any #RheumaPreg25 sessions?
No worries! Join the highlights webinar on May 26. Contact @karenschreiber.bsky.social or @lauraandreoli.bsky.social to join the #ReHFaP mailing list 📩
No worries! Join the highlights webinar on May 26. Contact @karenschreiber.bsky.social or @lauraandreoli.bsky.social to join the #ReHFaP mailing list 📩
May 9, 2025 at 2:14 PM
Prof. Angela Tincani (Brescia, Italy) talks about "Implications of New Classification Criteria of APS"
#RheumaPreg25
#RheumaPreg25
May 9, 2025 at 12:38 PM
Prof. Angela Tincani (Brescia, Italy) talks about "Implications of New Classification Criteria of APS"
#RheumaPreg25
#RheumaPreg25
2️⃣ Second session "Beyond the clot: challenges in obstetric antiphospholipid syndrome", chaired by Nathalie Costedoat-Chalumeau and Karoline Mayer-Pickel!
#RheumaPreg25 #APS #APSmatters #oAPS
#RheumaPreg25 #APS #APSmatters #oAPS
May 9, 2025 at 10:38 AM
2️⃣ Second session "Beyond the clot: challenges in obstetric antiphospholipid syndrome", chaired by Nathalie Costedoat-Chalumeau and Karoline Mayer-Pickel!
#RheumaPreg25 #APS #APSmatters #oAPS
#RheumaPreg25 #APS #APSmatters #oAPS
Day 2 of #RheumaPreg25, we kickoff talking about including pregnant patients in clinical trials.
Laura Andreoli kicks off @lauraandreoli.bsky.social by talking about pregnancy, medication, and the Future of Medical Research 👇
Laura Andreoli kicks off @lauraandreoli.bsky.social by talking about pregnancy, medication, and the Future of Medical Research 👇
May 9, 2025 at 10:05 AM
Day 2 of #RheumaPreg25, we kickoff talking about including pregnant patients in clinical trials.
Laura Andreoli kicks off @lauraandreoli.bsky.social by talking about pregnancy, medication, and the Future of Medical Research 👇
Laura Andreoli kicks off @lauraandreoli.bsky.social by talking about pregnancy, medication, and the Future of Medical Research 👇
It was a pleasure to participate in the session "Inclusion of pregnant patients with chronic conditions in research and clinical trials" in #RheumaPreg25
Such an honor to exchange with these wonderful women and incredible experts! 😍
Such an honor to exchange with these wonderful women and incredible experts! 😍
📍Estamos en Viena en #RheumaPreg25
Nuestra vicepresidenta trae la voz de pacientes al panel sobre los desafíos en la investigación en embarazo y lactancia con @lauraandreoli.bsky.social, Klara Rosta @rheproat.bsky.social, @karenschreiber.bsky.social Judit Sandor y @nelson-piercy.bsky.social
Nuestra vicepresidenta trae la voz de pacientes al panel sobre los desafíos en la investigación en embarazo y lactancia con @lauraandreoli.bsky.social, Klara Rosta @rheproat.bsky.social, @karenschreiber.bsky.social Judit Sandor y @nelson-piercy.bsky.social
May 9, 2025 at 9:46 AM
It was a pleasure to participate in the session "Inclusion of pregnant patients with chronic conditions in research and clinical trials" in #RheumaPreg25
Such an honor to exchange with these wonderful women and incredible experts! 😍
Such an honor to exchange with these wonderful women and incredible experts! 😍
Reposted by Silvia Aguilera
Day 2 of RheumaPreg 2025 is underway!
Today’s sessions focus on clinical research in pregnancy, obstetric APS, neonatal lupus, immunosuppression during pregnancy, and hormonal influences in rheumatic diseases.
Stay tuned for more insights and discussion.
Today’s sessions focus on clinical research in pregnancy, obstetric APS, neonatal lupus, immunosuppression during pregnancy, and hormonal influences in rheumatic diseases.
Stay tuned for more insights and discussion.
May 9, 2025 at 6:41 AM
Day 2 of RheumaPreg 2025 is underway!
Today’s sessions focus on clinical research in pregnancy, obstetric APS, neonatal lupus, immunosuppression during pregnancy, and hormonal influences in rheumatic diseases.
Stay tuned for more insights and discussion.
Today’s sessions focus on clinical research in pregnancy, obstetric APS, neonatal lupus, immunosuppression during pregnancy, and hormonal influences in rheumatic diseases.
Stay tuned for more insights and discussion.
Dr. Kazem Nouri: presents "Fertility Preservation in Rheumatic Diseases"
#RheumaPreg25
#RheumaPreg25
May 8, 2025 at 12:41 PM
Dr. Kazem Nouri: presents "Fertility Preservation in Rheumatic Diseases"
#RheumaPreg25
#RheumaPreg25
Dr. Klara Rosta: "How to approach infertility in rheumatic diseases" #RheumaPreg25
@rheproat.bsky.social
Reproductive Trends:
- Women having children later (avg. 31 years)
- Fertility peak: 20-35 years
- Reproductive potential declines after 35
- Biotechnology expanding fertility options 📊
@rheproat.bsky.social
Reproductive Trends:
- Women having children later (avg. 31 years)
- Fertility peak: 20-35 years
- Reproductive potential declines after 35
- Biotechnology expanding fertility options 📊
May 8, 2025 at 12:20 PM
Dr. Klara Rosta: "How to approach infertility in rheumatic diseases" #RheumaPreg25
@rheproat.bsky.social
Reproductive Trends:
- Women having children later (avg. 31 years)
- Fertility peak: 20-35 years
- Reproductive potential declines after 35
- Biotechnology expanding fertility options 📊
@rheproat.bsky.social
Reproductive Trends:
- Women having children later (avg. 31 years)
- Fertility peak: 20-35 years
- Reproductive potential declines after 35
- Biotechnology expanding fertility options 📊
Bettina Toth from Med Uni Innsbruck @i-med.ac.at talks about “Ovarian reserve: current diagnostic and therapeutic options”
#RheumaPreg25
#RheumaPreg25
May 8, 2025 at 11:32 AM
Bettina Toth from Med Uni Innsbruck @i-med.ac.at talks about “Ovarian reserve: current diagnostic and therapeutic options”
#RheumaPreg25
#RheumaPreg25